Concepedia

Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world

Toshirou Nishida, Shinsuke Sato, Masato Ozaka, Yujiro Nakahara, Yoshito Komatsu, Masato Kondo, Haruhiko Cho, Seiichi Hirota, Tatsuo Kagimura, Yukinori Kurokawa,

Gastric Cancer · 2022 · 25 citations · 16 references

DOIFull text

Open access

Concepts

References

16

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

George D. Demetri, Margaret von Mehren, Charles D. Blanke et al. · New England Journal of Medicine · 2002 · 4.4K citations · Full text

, , +14

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Ronald P. DeMatteo, Karla V. Ballman, Cristina R. Antonescu et al. · The Lancet · 2009 · 1.4K citations · Full text

, , +11

NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors

George D. Demetri, Margaret von Mehren, Cristina R. Antonescu et al. · Journal of the National Comprehensive Cancer Network · 2010 · 1.2K citations

, , +17

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Charles D. Blanke, Cathryn Rankin, George D. Demetri et al. · Journal of Clinical Oncology · 2008 · 1.1K citations

, , +13

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall et al. · JAMA · 2012 · 969 citations

, , +12